EGFR and non-small cell lung carcinoma: These findings suggest that combination therapies that include chemical inhibitors to cell cycle processes and ubiquitin regulation pathways can serve as novel treatment strategies to overcome erlotinib resistance for EGFR mutant patients with NSCLC.